Who are Aureotan's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lotronex, Anzemet, Isocain, Lignocaine, Namenda, xylocain.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aurothioglucose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Aureotan — Competitive Intelligence Brief

Aureotan (aurothioglucose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: aurothioglucose. Area: Immunology.

marketed aurothioglucose 5-hydroxytryptamine receptor 3A Immunology Live · refreshed every 30 min

Target snapshot

Aureotan (aurothioglucose).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aureotan TARGET	aurothioglucose		marketed	aurothioglucose	5-hydroxytryptamine receptor 3A
Lotronex	ALOSETRON	Legacy Pharma	marketed	Serotonin-3 Receptor Antagonist	5-hydroxytryptamine receptor 3A	2000-01-01
Anzemet	DOLASETRON	Validus Pharms	marketed	Serotonin-3 Receptor Antagonist	5-hydroxytryptamine receptor 3A	1997-01-01
Isocain	PROCAINE	Pfizer	marketed	Amide Local Anesthetic [EPC]	5-hydroxytryptamine receptor 3A	1954-01-01
Lignocaine	Lignocaine	University of Malaya	marketed		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
Namenda	Namenda	Inova Health Care Services	marketed		Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 3A, Acetylcholinesterase
xylocain	xylocain	Saint-Joseph University	marketed		5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (aurothioglucose class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aureotan — Competitive Intelligence Brief. https://druglandscape.com/ci/aurothioglucose. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab